CN106555004A - The lncRNA marks of cerebral infarction - Google Patents
The lncRNA marks of cerebral infarction Download PDFInfo
- Publication number
- CN106555004A CN106555004A CN201611051596.3A CN201611051596A CN106555004A CN 106555004 A CN106555004 A CN 106555004A CN 201611051596 A CN201611051596 A CN 201611051596A CN 106555004 A CN106555004 A CN 106555004A
- Authority
- CN
- China
- Prior art keywords
- lncrna
- sequence
- product
- seq
- linc00189
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses the lncRNA marks of cerebral infarction, the lncRNA marks are LINC00189 and LOC105376014, wherein LINC00189 up-regulateds in ischemic cerebral stroke patients, LOC105376014 down-regulated expressions in ischemic cerebral stroke patients.LncRNA marks provided by the present invention, can be used for the early diagnosiss of cerebral infarction, with higher sensitivity and specificity.
Description
Technical field
The invention belongs to biomedicine field, is related to the lncRNA marks of cerebral infarction.
Background technology
Great public health problem of the apoplexy as the whole world, is a kind of dyskinetic disease of cerebral blood circulation of unexpected onset
One of disease, and the principal disease of harm human health.Apoplexy has become the worldwide second largest cause of death and cause
Residual first cause.Resulted in soldier in dead crowd, developing country is concentrated on more than 2/3rds.There is data to show,
About 2.3 hundred million people of China suffers from cardiovascular diseasess, and patients with cerebral apoplexy is more than 7,000,000.One growing up comprising 169,871 40 years old and the above
The perspective queue of people is ground the result that makes internal disorder or usurp and is shown, apoplexy occupies the 2nd cause of the death of the 3rd cause of the death and women of male, male's brain
Apoplexy mortality rate is 310.5/100,000 man-year, accounts for the 21.6% of total death, and women apoplexy mortality rate is 242.3/100,000
Man-year, accounts for the 20.8% of total death.The high incidence of apoplexy, high relapse rate, high disability rate and high fatality rate, to patient home
White elephant is caused with society.There is data to show, China is used for treating the costly up to tens billion of first people of apoplexy every year
People's coin, apoplexy have become the important Disease Spectrum of China and great public health problem.Cerebral infarction is also called
Cerebral infarction, it is the local brain tissue area blood supply obstacle caused by a variety of causes, causes brain tissue ischemia anoxia sexually transmitted disease (STD)
Become necrosis, and then produce clinically corresponding neurological deficit performance.Ischemic Stroke is the main Types of apoplexy, accounts for soldier
In total morbidity 60%～80%.At present it has been recognized that apoplexy is a kind of coefficient by environmental factorss, inherited genetic factorss etc.
Complex disease, the pathogenesis and the early diagnosiss of the relation pair apoplexy of inherited genetic factorss and prevention for understanding apoplexy have important
Meaning.
With developing rapidly for microarray technology and Nucleic acid sequencing techniques, scientist is had found only 2% in human genome
Sequential coding produce protein, protein coding gene number deficiency 30,000, and remaining nearly 98% genome sequence turns
Record generates a large amount of and miscellaneous non-coding RNA, and these ncRNA are the important sets of complicated regulated and control network in body
Into part.
Long-chain non-coding RNA (long noncoding RNA, lncRNA) is that a class can be sent out during various biological
Wave the macromole ncRNA of regulating and controlling effect.Which is widely distributed, and length is typically greater than 200 bases, due to lacking effective open reading
Frame (ORF) and without or seldom have the ability of encoding proteins.A uncharted field in as molecular biology, lncRNA be with
The form of RNA play on many levels controlling gene expression effect, mainly epigenetic regulation, transcriptional control and
Three aspects of post-transcriptional control are regulated and controled.Used as the important component part of mammalian transcription group, the function of lncRNA is current
It need to be furtherd investigate.Initially lncRNA is considered as the by-product of rna plymerase ii transcription, is that subgenomic transcription " is made an uproar
Sound ", " dark matter ", not with biological function.But result of study in recent years shows, lncRNA is in cell normal physiological activity
Important function and participate in the generation development of kinds of tumors and other diseases.LncRNA not only participates in transport in core, turns
In the cellular physiological events such as record regulation and control, protein degradation, genomic imprinting and X chromosome silence, also with breast carcinoma, carcinoma of prostate,
The pathogenesis of the diseases such as nonsmall-cell lung cancer, lymphoid leukemia are relevant.LncRNA can pass through Genomic Imprinting, chromatin weight
Structure, shearing regulation and control, mRNA degradeds and the mechanism such as translational control are implementing its function.Although lncRNA correlational studyes are obtained in recent years
Progress, but its function and mechanism of action still need further to be explored.Research lncRNA main methods and instrument include chip,
RNA sequencings, real-time quantitative PCR, Northern blotting, in situ hybridization, RNAi, RIP and Bioinformatics Prediction etc..Grind
The development and utilization of technology is studied carefully for the research of biological mechanism is very crucial.
LncRNA is widely present in Various Tissues, and its expression is with tissue specificity and Space-time speciality.Meanwhile,
LncRNA also has the expression pattern of specificity in tumor and other diseases.Currently for lncRNA in disease of brain field
Research is still in the starting stage, seeks effects of the lncRNA in cerebral infarction significant.
The content of the invention
In order to make up the deficiencies in the prior art, an object of the present invention, there is provided a kind of early stage cerebral infarction is examined
Pregnancy ceased product, make patient just be prevented in early stage, and then improve survival rate and quality of life.
The second object of the present invention, there is provided a kind of diagnostic method of cerebral infarction, by the expression for detecting lncRNA
Whether level diagnosing patient with cerebral infarction.
The third object of the present invention, there is provided a kind of molecular marker, as the Testing index of clinical practice.
To achieve these goals, the present invention is adopted the following technical scheme that：
The invention provides a kind of cerebral infarction diagnosis uses lncRNA marks, the lncRNA to include
LINC00189。
In the present invention, LINC00189 refers to gene or the mRNA from the genetic transcription, in the mankind, positioned at No. 21 chromosomes
Long-armed 2nd area 1 is with 3 subzones.The gene is with three annotations transcript (or splice variant)：The LINC00189-001 of long 989bp
LINC00189-003 (the turning in Ensembl of (the transcript ID in Ensembl is ENST00000420364.1), long 783bp
This ID is recorded for ENST00000447125.5) and the LINC00189-002 of long 308bp (the transcript ID in Ensembl is
ENST00000431661.1).In particular embodiments, LINC00189 gene outcomes refer to long transcript.
Further, the sequence of the LINC00189 is as shown in SEQ ID NO.1.
Further, the lncRNA marks also include that LOC105376014, the lncRNA are located at No. 9 the short arm of a chromosome 2
Area 1 takes, and including two transcripts, length is the XR_ of XR_929550.2.1 and length for 938bp of 1335bp
001746646.1.1.In the specific embodiment of the present invention, LOC105376014 refers to long transcript, sequence such as SEQ ID
Shown in NO.2.
The invention provides above-mentioned lncRNA biomarkers are being prepared or are being screened in cerebral infarction diagnostic products
Application.
Further, the product includes：By sequencing technologies, nucleic acid hybridization technique, nucleic acid amplification technologies or immunoassay
Method detect the expression of lncRNA recited above.In the present invention, LINC00189 is in ischemic cerebral stroke patients
Up-regulated, LOC105376014 down-regulated expressions in ischemic cerebral stroke patients.
Further, the nucleic acid amplification technologies are situated between selected from polymerase chain reaction, reverse transcriptase polymerase chain reaction, transcription
Amplification, ligase chain reaction, strand displacement amplification and the amplification based on nucleotide sequence led.
The invention provides a kind of product, the product includes chip, preparation or test kit, and which can be determined in sample such as
The expression of upper described lncRNA.
Further, the chip includes：Solid phase carrier；And the oligonucleotide being fixed on the solid phase carrier in order is visited
Pin, the oligonucleotide probe part or all of sequence specifically corresponding to lncRNA recited above.Wherein, solid phase is carried
Body includes but is not limited to sheet glass, silicon chip, polypropylene screen, nitrocellulose filter, nylon membrane or polystyrene film.
Further, the test kit includes the probe of the specificity of the lncRNA for detecting above-mentioned, gene chip, or PCR draws
Thing.
Further, the PCR primer sequence such as SEQ ID NO.3 and SEQ ID NO.4 institutes of LINC00189 specificitys are detected
Show；The PCR primer sequence of detection LOC105376014 specificitys is as shown in SEQ ID NO.5 and SEQ ID NO.6.
Further, it is described state test kit may also include dNTP, random primer, reducing agent, RNase inhibitor, reverse transcription,
MgCl2With the combination of one or more in PCR buffer etc., additionally, the test kit can also contain standard substance and/or right
According to product；In a preference of the present invention, GAPDH has been selected as internal reference.
Further, mentioned reagent box preferably also includes some other auxiliary reagent, and described auxiliary reagent is quantitative PCR
Conventional use of some reagents in amplification kit, the characteristic of these reagents and their compound method are art technologies
Known to personnel；Described reagent is such as (but not limited to)：Negative controls, positive reference substance；Can also be fixed including fluorescence
Amount PCR Sptting plates, PCR Sptting plate sealed membranes etc..
The invention provides application of the said goods in the instrument for preparing diagnosing ischemia apoplexy.
The invention provides a kind of product of diagnosing ischemia apoplexy, the product can be by detecting in sample
The expression of LINC00189 carrys out diagnosing ischemia apoplexy." sample " including cell, tissue, internal organs, cerebrospinal fluid, body
Liquid (blood, lymph fluid etc.), Digestive system, expectoration, alveole bronchus cleanout fluid, urine, feces etc..Preferably, the sample is group
Knit, blood.In the specific embodiment of the present invention, sample is blood.
" probe " refers to the molecule that can be combined with the particular sequence of another molecule or subsequence or other parts.Unless otherwise finger
Go out, term " probe " is often referred to be matched by complementary base and is combined with another polynucleotide (often referred to as " target polynucleotide ")
Polynucleotide probes.It is many according to the preciseness of hybridization conditions, probe energy and the target complementary with probe shortage sufficient sequence
Nucleotide is combined.Probe can make direct or indirect labelling, and its scope includes primer.Crossing system, includes, but are not limited to：It is molten
Liquid phase, solid phase, mixed phase or in situ hybridization algoscopy.
The probe is with the base sequence with the specific base sequence complementary of target gene.Here, so-called " complementation ",
As long as hybridization, can not be complete complementary.These polynucleotide are commonly angled relative to the specific base sequence to be had
More than 80%, preferably more than 90%, more preferably more than 95%, particularly preferred 100% homology.These probes can be DNA,
Can also be RNA, furthermore it is possible to be to pass through PNA (Polyamide nucleic in one part or whole nucleotides
Acid, peptide nucleic acid(PNA)), LNA (registered trade mark, locked nucleic acid, Bridged Nucleic Acid, Cross-linked core
Acid), ENA (registered trade mark, 2 '-O, 4 '-C-Ethylene-bridged nucleic acids), GNA (Glycerol
Nucleic acid, glycerol nucleic acid), the artificial replacement nucleic acid such as TNA (Threose nucleic acid, threose nucleic acid) obtains
Polynucleotide.
In the present invention, gene detecting kit or gene chip can be used for detection includes LINC00189 and LOC105376014
Expression of the gene in interior multiple genes (for example, the multiple genes related to cerebral infarction), by ischemic cerebral apoplexy
In multiple marks simultaneously detected, be greatly improved the accuracy rate of cerebral infarction diagnosis.
It would be recognized by those skilled in the art that the practicality of the present invention is not limited to the marker gene to the present invention
The gene expression of any specific variants is carried out quantitatively.Used as nonrestrictive example, marker gene can have SEQ ID NO.1
And/or the cDNA sequence that SEQ ID NO.2 are specified.In some embodiments, which has and listed sequence at least 85% phase
With or similar cDNA sequence, all sequences listed as described above at least 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%th, 98% or at least 99% same or analogous cDNA sequence.
In the present invention, term " homology " " refer to complementary degree.There may be Homoeology or complete homology
(that is, homogeneity).The sequence of partial complementarity is the nucleic acid molecules and " substantially homologous " for suppressing complete complementary at least in part
The nucleic acid molecules of target nucleus acid hybridization.The suppression of fully-complementary sequence and the hybridization of target sequence can be by making under low stringency
Checked with hybridization assays (Southern or Northern traces, solution hybridization etc.).Substantially homologous sequence or probe
By compete and suppress completely homologous nucleic acid molecules under low stringency and target combination (that is, hybridizing).This is not
Say, low stringency is so that the condition for allowing non-specific binding；Between low stringency requires two sequences
The interaction for being combined into specificity (that is, selectivity).Not existing for non-specific binding can be by using substantially non-mutual
The second target for mending (for example, below about 30% homogeneity) is tested；In the case where there is no non-specific binding, probe
Will not with the second incomplementarity target hybridization.
In the present invention, term " stringency " is for referring to the condition for carrying out residing for nucleic acid hybridization：Temperature, ionic strength and its
The presence of his compound (such as organic solvent).Under " low stringency condition ", nucleotide sequence of interest will be with its exact complementarity
Sequence, the sequence with single base mispairing, closely related sequence (for example, the sequence with 90% or more high homology) with
And only sequence (for example the sequence, with the 50-90% homologys) hybridization of Homoeology.At " medium stringent conditions "
Under, nucleotide sequence of interest by only with its exact complementary sequence, the sequence with single base mispairing and closely related sequence
Row (for example, 90% or more high homology) hybridization.Under " high stringency ", nucleotide sequence of interest will be only accurate with which
Complementary seriess and the sequence hybridization of (depending on the condition of such as temperature) with single base mispairing.In other words, high strict
Under the conditions of property, high-temperature can be risen to exclude and the sequence hybridization with single base mispairing.
The LINC00189 gene product expressions referred in the present invention are raised, and refer to the higher level than normal presence.It is logical
Often, this can be by estimating with comparing.According to specific embodiment, the level that lncRNA increases is higher than compareing
10%th, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, 100%, 150%, 200% or very
To higher level.According to another specific embodiment, it is intended that LINC00189 gene product expressions or presence, and its
Under normal circumstances (or in control) disappearance.In other words, in these embodiments, determine LINC00189 gene outcomes to increase
Plus expression equivalent to detection LINC00189 gene outcomes presence.Generally, this in this case, will be including control guaranteeing
Detection reaction is correctly carried out.
The LOC105376014 down-regulated expressions referred in the present invention, refer to the lower level than normal presence, and this can pass through
Estimate with comparing, suitable control is included but is not limited to, the similar sample, control from the experimenter for not having apoplexy
In the average level of group (or compared with control cells) or one group of relevant sampling tissue, LOC105376014 gene outcome average levels faces
Bed data.
The advantages of the present invention：
Present invention firstly discovers that there is the related lncRNA of development to cerebral infarction, by detecting the lncRNA's
Expression can be detected to early stage cerebral infarction, so as to treat to early stage ischemic cerebral stroke patients, be carried
The life quality of high patient.
The present invention provide biomarker carry out Combining diagnosis, can, specificity higher with sensitivity it is higher.
Description of the drawings
Fig. 1 shows the difference expression gene using cDNA microarray ischemic cerebral stroke patients；
Fig. 2 to show and detect expressions of the lncRNA in ischemic cerebral stroke patients using QPCR.
Specific embodiment
The present invention is further detailed explanation with reference to the accompanying drawings and examples.Following examples are merely to illustrate this
Invention rather than restriction the scope of the present invention.The experimental technique of unreceipted actual conditions in embodiment, generally according to conventional strip
Part, such as Sambrook et al., molecular cloning：Laboratory manual (New York:Cold Spring HarborLaboratory
Press, 1989) described in condition, or according to the condition proposed by manufacturer.
Embodiment 1 screens the gene marker related to cerebral infarction
1st, sample collection
The blood of 10 normal human bloods and ischemic cerebral stroke patients is collected respectively, the equal informed consent of patient is above-mentioned all
The acquirement of specimen is by the agreement of committee of organizational ethics.
2nd, the preparation of RNA sample
1) 12000rpm high speed centrifugation 10min after clinical serum sample collection, are repeated 2 times, -80 DEG C of guarantors of gained serum sample
Deposit；
2) 4 DEG C of defrostings of frozen serum sample；
3) serum sample for drawing 250 μ 1 is managed to 1.5m1EP, plus 750 μ 1Trizol LS Reagent, and piping and druming is mixed, quiet
Put 5min；
4) imitative (CHCl of chlorination3：trizol250μ1:1) 750 μ, overturn and mix, and stand 15min；
5) 4 DEG C, 12000rpm is centrifuged 15min；
6) careful supernatant liquid of drawing is to a new EP pipes；
7) add appropriate isopropanol (isopropanol：trizo1500μ1：1) 750 μ, overturn and mix, and stand 10min；
8) 4 DEG C, 12000rpm centrifugation 10min；
9) upper strata centrifugal liquid, plus 75% ethanol (RNase inactivation) are abandoned；
10) 4 DEG C, 8000rpm centrifugation 5min；
11) retain precipitation, abandon upper strata centrifugal liquid, be stored at room temperature 5-10min；
12) appropriate DEPC water dissolutioies precipitation, takes appropriate RNA solution and surveys concentration and observation RNA extracting situations；
13) labelling title, concentration and mouth phase, -80 DEG C of preservations.
3rd, reverse transcription and labelling
With Low RNA Input Linear Amplification Kit by mRNA reverse transcriptions into cDNA, while using Cy3
Difference labelling experiment group and matched group.
4th, hybridize
Gene chip adopts Kang Cheng biology-Human lncRNAArray, carries out the step of by chip operation instructions miscellaneous
Hand over.
5th, data processing
Chip Agilent scanner scannings after hybridization, resolution are 5 μm, and scanner is automatically with 100% and 10%PMT
Each scanning 1 time, 2 times result Agilent software merges automatically.Scan image data using Feature Extraction at
Reason analysis, the initial data application Bioconductor program bags for obtaining carry out follow-up data process.Last Ratio values are experiment
Group and matched group.Differential gene screening criteria：Ratio >=4 are up-regulated gene, and ratio≤0.25 is down-regulated gene.
6th, result
As a result as shown in figure 1, compared with healthy human blood, expression water of the LINC00189 in ischemic cerebral stroke patients
The flat expression for being significantly higher than Healthy People；Expressions of the LOC105376014 in ischemic cerebral stroke patients is substantially less than
The expression of Healthy People.
The differential expression of 2 QPCR sequence verification LINC00189 genes of embodiment
1st, large sample QPCR checkings are carried out to the lncRNA of gene differential expression.According to the sample collection side in embodiment 1
The blood sample sample of formula selection normal person and ischemic cerebral stroke patients is each 100.
2nd, RNA extraction steps are with embodiment 1.
3rd, reverse transcription：
(1) reverse transcription reaction：
Using 25 μ l reaction systems, each sample takes 1 μ g total serum IgEs as template ribonucleic acid, is separately added into following in PCR pipe
Component：DEPC water, 5 × RT Buffer, 10mM dNTP, 0.1mM DTT, 30 μM of OligodT, 200U/ μ l M-MLV, mould
Plate RNA.42 DEG C of incubation 1h, 72 DEG C of 10min, of short duration centrifugation.(2) design of primers：
The primer sequence of LINC00189 genes is：
Forward primer：5’-TCTTTGATTGACTGATTCTTT-3’(SEQ ID NO.3)
Reverse primer：5’-TTGAGGAACACATCTGAA-3’(SEQ ID NO.4)
The primer sequence of LOC105376014 genes is：
Forward primer：5’-TTGTTCTTGTGTCTGTTCT-3’(SEQ ID NO.5)
Reverse primer：5’-CTGCTACTGTGCTTCTAC-3’(SEQ ID NO.6)
The primer sequence of house-keeping gene GAPDH is：
Forward primer：5’-CCGGGAAACTGTGGCGTGATGG-3’(SEQ ID NO.7)
Reverse primer：5’-AGGTGGAGGAGTGGGTGTCGCTGTT-3’(SEQ ID NO.8)
(3) QPCR amplifications inspection：
Using 25 μ l reaction systems, each sample arranges 3 parallel pipes, all amplified reactions in triplicate more than protecting
The reliability of card result.
Prepare following reaction system：12.5 μ l of SYBR Green polymerase chain reactions system, forward and reverse primer (5 μM)
Each 1 μ l, 2.0 μ l of template cDNA, without 8.5 μ l of enzyme water.Operations are carried out on ice.
Amplification program is：95 DEG C of 60s, (95 DEG C of 15s, 60 DEG C of 15s, 72 DEG C of 45s) × 35 circulations.
It is using SYBRGreen as fluorescent marker, anti-in the enterprising performing PCR of Light Cycler fluorescence real-time quantitative PCR instrument
Should, purpose band is determined by melt curve analysis analysis and electrophoresis, Δ Δ CT methods carry out relative quantification.
3rd, statistical method
Experiment is all completed according to being repeated 3 times, result data be all in the way of mean+SD representing,
Statistical analysiss are carried out using SPSS18.0 statistical softwares, difference between the two is checked using t, it is believed that work as P<Have when 0.05
It is statistically significant.
4th, result
As a result as shown in Fig. 2 compared with Healthy People, LINC00189 genes up-regulated in ischemic cerebral stroke patients,
Down-regulated expressions of the LOC105376014 in ischemic cerebral stroke patients, difference have statistical significance (P<0.05), same to chip
Testing result is consistent.
The explanation of above-described embodiment is only intended to understand the method for the present invention and its core concept.It should be pointed out that for this
For the those of ordinary skill in field, under the premise without departing from the principles of the invention, some improvement can also be carried out to the present invention
And modification, these improve and modification will be also fallen in the protection domain of the claims in the present invention.
SEQUENCE LISTING
<110>The First Hospital of Medical College of Shantou University
<120>The lncRNA marks of cerebral infarction
<160> 8
<170> PatentIn version 3.5
<210> 1
<211> 989
<212> DNA
<213>People source
<400> 1
ttacaagtga actttctttc ctgttttaaa gccttttaaa taaacttcca ctcctgtgct 60
gaaacttgcc ttagtctttt tttctgcttt atgcccctca gtcgaattct ttcatctgag 120
gaggcaagaa ttgaagttgc tgcagacgcc tgtggattca ccacaagtac attggagtaa 180
ccactgggaa caacaggttg ccttagaagc tttgcaggtt gttttgtttt tttgtttgtt 240
tgtttttttg agacggggtc tcactttgtc gcccaggttt gttgcccagg ctggagtgca 300
gtggcgcaat ctcggctctc cgcaacctct gcctcccggg ctcaagtgat cctcccacct 360
cggcttcccg agtacctggg actacaggca tgcaccacca cacccggcta attttaattt 420
ttattttgta tttttagtag agttggggtt tcaccatgtt cccagctggt cttgaactct 480
tgaggtgaag caatccgccc acctcagcct cccaaagtgc tgagattaca gacgtgagcc 540
atcgcgccta gccttgcaag ttgttttttg ttgaacagaa gaagctattc aaaaatgtcc 600
aggactctgt tatttattca gcaagcttac aaagccatct ttgattgact gattctttga 660
caatgactat ctggatgaca caggaaggat gcaattctgg ccttggagag aaaacttgca 720
aggaaaggaa catgtttgaa tttcagatgt gttcctcaat gaatcacgat cttcagggaa 780
tgtttcaggt ggaggaaggg gctcttggtc aatgagcctg aagactgcat ggcaaccttt 840
gccagctttt ggcctgaaaa ctcaacttct tcatttgaga taattcctgt tttatatact 900
ttcatttgag atattcctgg tgtatcaact gaaacaaaat ctatgaaata tcagattcac 960
aaaaatacat tttgaatatt gaacgtgga 989
<210> 2
<211> 1335
<212> DNA
<213>People source
<400> 2
ttatttgaat ttcaaacaac agaccaacca tagctcaatg tttctcaaga gtatcctgtg 60
gagcacagtg cgtgaacgcc cagaagaaag cagtctgtgg tcaggtgggt ttctgtgcca 120
tttgctgcca ccttccctgc aaacagtgat ttacagcaca cattgttctt gtgtctgttc 180
tgcagtgata aaacccattt aactcagtgg ttcccaaatg tactgaccgt ggaactgttt 240
tactcagggg acactgttaa catcctgtag aagcacagta gcaggtatcc agcctgcata 300
cgataagaca accagaacca aatttggcag gtacatgtct ggaactctgt ttcattatgc 360
cgtaaaataa aactacgaat ttcattcaac aaatctgtac tgaataagta ggcttcactc 420
ttgggatgtc aacttttaaa acttacttaa tatcagctat cgttatataa tctttgttca 480
taatgacgct gtctggttga acacaaactg gctgggtgtt aaattccact tgtgtttatg 540
atatttaata atgtcctaag aaggcagcca gtagaacctt ggctactgtt tttcaaaagt 600
ggctctgcat tgctcctaca taaccccgta cattactcca cagtcctgtt agagccctga 660
aagggaaact gctaaaaata aggttcttca tttaggtgac taggaactcc caatattttt 720
gccctaggga atactgggag acaaatctct acgatcacaa attactaatg gtttccccag 780
aactgctggt ggccatatcc cctggcatgt ggaagggccc agaagaggcc actctactgc 840
agaggccaac agaagagtgt tgcccaggct ggtctcaaac ttctgggctc aagcaaccct 900
ccagcctcgg cctcccaaag tgttgggatc ataggcatga gacaccgtgc ctggcgaaga 960
tatttttacc gaaaaggaca gagggtgtac ttggaggcac ataccaaaga aatgccatgt 1020
gagaacaagc aagaaggtgg ccatctgtaa accaggaaga gtgtcctcac cagaaaatga 1080
agtggcttca actttgatct cagaattcca gcctccataa ctgtgagaaa atacatttct 1140
gttctttcag ccagtctatg gcattacatt atagcaaccc aagcaaacta aggcatgccc 1200
agaaatgact acaggggtaa aaatgagcag ataattggtt tttagtgtcc tgaagtttat 1260
ctgcttttcc ttatgtactt atatcgttgc cactgccacc aggctactct tccttcttgt 1320
ctgctcccaa acagg 1335
<210> 3
<211> 21
<212> DNA
<213>Artificial sequence
<400> 3
tctttgattg actgattctt t 21
<210> 4
<211> 18
<212> DNA
<213>Artificial sequence
<400> 4
ttgaggaaca catctgaa 18
<210> 5
<211> 19
<212> DNA
<213>Artificial sequence
<400> 5
ttgttcttgt gtctgttct 19
<210> 6
<211> 18
<212> DNA
<213>Artificial sequence
<400> 6
ctgctactgt gcttctac 18
<210> 7
<211> 22
<212> DNA
<213>Artificial sequence
<400> 7
ccgggaaact gtggcgtgat gg 22
<210> 8
<211> 25
<212> DNA
<213>Artificial sequence
<400> 8
aggtggagga gtgggtgtcg ctgtt 25
Claims (10)
1. lncRNA marks are used in a kind of cerebral infarction diagnosis, it is characterised in that the lncRNA includes LINC00189.
2. mark according to claim 1, it is characterised in that the sequence of the LINC00189 such as SEQ ID NO.1 institutes
Show.
3. lncRNA marks are used in cerebral infarction diagnosis according to claim 1, it is characterised in that the lncRNA
Also include LOC105376014.
4. the lncRNA biomarkers described in any one of claim 1-3 are being prepared or are screening cerebral infarction diagnostic products
In application.
5. application according to claim 4, it is characterised in that the product includes：By sequencing technologies, nucleic acid hybridization skill
The method test right of art, nucleic acid amplification technologies or immunoassay requires the expression of lncRNA described in any one of 1-3.
6. a kind of product, the product include chip, preparation or test kit, it is characterised in that the product can determine sample
In lncRNA as described in any one of claim 1-3 expression.
7. product according to claim 6, it is characterised in that the chip includes：Solid phase carrier；And be fixed in order
Oligonucleotide probe on the solid phase carrier, the oligonucleotide probe specifically correspond to any one of claim 1-3
The part or all of sequence of described lncRNA.
8. product according to claim 7, it is characterised in that the test kit is included to any one of claim 1-3 institute
The lncRNA for stating has the probe of detection specificity, gene chip, or PCR primer.
9. product according to claim 8, it is characterised in that the PCR primer sequence of detection LINC00189 specificitys is such as
Shown in SEQ ID NO.3 and SEQ ID NO.4；The PCR primer sequence such as SEQ ID NO.5 of detection LOC105376014 specificitys
With shown in SEQ ID NO.6.
10. application of the product described in any one of claim 6-9 in the instrument for preparing diagnosing ischemia apoplexy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611051596.3A CN106555004B (en) | 2016-11-24 | 2016-11-24 | The lncRNA markers of cerebral arterial thrombosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611051596.3A CN106555004B (en) | 2016-11-24 | 2016-11-24 | The lncRNA markers of cerebral arterial thrombosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106555004A true CN106555004A (en) | 2017-04-05 |
| CN106555004B CN106555004B (en) | 2018-10-02 |
Family
ID=58445060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611051596.3A Active CN106555004B (en) | 2016-11-24 | 2016-11-24 | The lncRNA markers of cerebral arterial thrombosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106555004B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107034275A (en) * | 2017-04-24 | 2017-08-11 | 王思奎 | A kind of purposes of the gene related to cerebral apoplexy generation development |
| CN109628594A (en) * | 2018-12-27 | 2019-04-16 | 河北医科大学第二医院 | One kind long-chain non-coding RNA relevant to liver cancer and its application |
| CN110042155A (en) * | 2019-04-08 | 2019-07-23 | 东莞市第三人民医院（东莞市石龙人民医院） | Detect Patients with Cerebral Infarction circulation LncRNA marker and its kit and application |
| CN110273001A (en) * | 2019-07-16 | 2019-09-24 | 天津市泌尿外科研究所 | One kind circRNA relevant to prostate cancer and its application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105296659A (en) * | 2015-11-30 | 2016-02-03 | 北京泱深生物信息技术有限公司 | Gene marker related to ischemic stroke |
| CN105925714A (en) * | 2016-07-01 | 2016-09-07 | 北京泱深生物信息技术有限公司 | Molecular marker for diagnosing cerebral ischemic thrombosis |
-
2016
- 2016-11-24 CN CN201611051596.3A patent/CN106555004B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105296659A (en) * | 2015-11-30 | 2016-02-03 | 北京泱深生物信息技术有限公司 | Gene marker related to ischemic stroke |
| CN105925714A (en) * | 2016-07-01 | 2016-09-07 | 北京泱深生物信息技术有限公司 | Molecular marker for diagnosing cerebral ischemic thrombosis |
Non-Patent Citations (2)
| Title |
|---|
| NR_027072.2: "Homo sapiens long intergenic non-protein coding RNA 189(LINC00189),long non-coding RNA", 《GENBANK》 * |
| XR_929550.2: "PREDICTED:Homo sapiens uncharacterized LOC105376014(LOC 105376014),transcript variant X1,ncRNA", 《GENBANK》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107034275A (en) * | 2017-04-24 | 2017-08-11 | 王思奎 | A kind of purposes of the gene related to cerebral apoplexy generation development |
| CN109628594A (en) * | 2018-12-27 | 2019-04-16 | 河北医科大学第二医院 | One kind long-chain non-coding RNA relevant to liver cancer and its application |
| CN110042155A (en) * | 2019-04-08 | 2019-07-23 | 东莞市第三人民医院（东莞市石龙人民医院） | Detect Patients with Cerebral Infarction circulation LncRNA marker and its kit and application |
| CN110273001A (en) * | 2019-07-16 | 2019-09-24 | 天津市泌尿外科研究所 | One kind circRNA relevant to prostate cancer and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106555004B (en) | 2018-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008510454A (en) | Identification of markers in lung and breast cancer | |
| EP2703488B1 (en) | Composition and method for predicting response to trastuzumab therapy in breast cancer patients | |
| CN106337089B (en) | A kind of lncRNA for cerebral arterial thrombosis diagnosis | |
| CN106555004B (en) | The lncRNA markers of cerebral arterial thrombosis | |
| CN108949992B (en) | Biomarker related to esophageal squamous carcinoma and grading thereof | |
| CN111662982B (en) | Biomarker for early diagnosis and/or recurrence monitoring of brain glioma and application thereof | |
| CN107858434B (en) | Application of lncRNA in liver cancer diagnosis and prognosis prediction | |
| CN106319089B (en) | Applications of the lncRNA in cerebral arterial thrombosis diagnosis | |
| CN109735623B (en) | Colorectal cancer biomarker | |
| CN106676191B (en) | A kind of molecular marker for adenocarcinoma of colon | |
| JP7392048B2 (en) | Analysis method and kit | |
| CN108676872A (en) | A kind of and the relevant biomarker of asthma and its application | |
| KR102414106B1 (en) | Multiple biomarkers for diagnosis of breast cancer and Uses thereof | |
| CN110331207A (en) | Adenocarcinoma of lung biomarker and related application | |
| EP4112745A1 (en) | Biomarkers for predicting a patient's response to bcg therapy, methods and uses based thereon | |
| AU2009213671A1 (en) | Colon cancer associated transcript 1 (CCAT1) as a cancer marker | |
| EP2906713A1 (en) | Micro-rna biomarkers for prostate cancer | |
| KR102096499B1 (en) | MicroRNA-3960 for diagnosing or predicting recurrence of colorectal cancer and use thereof | |
| WO2014093504A1 (en) | Microrna biomarkers for graft versus host disease | |
| JP7346533B2 (en) | Analysis method and kit | |
| KR102548873B1 (en) | A method for sorting colorectal cancer and advanced neoplasia and use of the same | |
| CN113881672B (en) | Hepatitis B virus infected miRNA molecular marker combination and application thereof | |
| KR20240058548A (en) | Extracellular vesicles-derived miRNA gene biomarkders for diagnosis or prediction of recurrence of breast cancer and use thereof | |
| CN106435010B (en) | The diagnosis marker of Bgudd-Chiari Syndrome | |
| KR20230156518A (en) | Early cancer diagnosis method and diagnostic kit using interferon gamma gene concentration measurement in exosomes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |